Issue 1867: April 1, 2026

The Immunize.org team is pleased to introduce durable, laminated tables of QR codes linking to VISs for vaccines given to children and adults. VISs explain both risks and benefits of vaccination. Federal law requires you to document provision of CDC’s current VIS before administering any vaccine covered by the Vaccine Injury Compensation Program. CDC recommends VISs accompany other vaccines, too. An easy, paperless way to comply with the law is for patients to scan a QR code and access the VIS from a smartphone or tablet. 

CDC produces official VISs only in English. CDC does not produce or certify available translations, so the official CDC VIS should accompany any translation.

These new tables belong in any room where vaccinations are given. Key features include: 

• Durable quality: The tough laminate coating can be wiped down.
• Never out-of-date: Any time a VIS or translation is updated, the QR code will direct to the new VIS.  
• Use as a booklet or poster: The laminated table arrives folded like a newspaper. It is suitable for desk use as an 8.5" x 11" booklet or wall mounted as an 11" x 17" poster.
• One version for official CDC VISs and one for Spanish translations: The table of official CDC VISs in English is sold individually. The table of Spanish translations is sold as a bundle with the table of official VISs so it is easy to make both available.
• Spanish version usable by non-Spanish speakers: The Spanish QR code table has side-by-side text in English to support its use by non-Spanish speakers.
• Easy access to all available translations: Both versions include a QR code link to the Immunize.org index of all VIS translations available in dozens of languages.
• Bonus content: The reverse side of the QR code poster includes links to Immunize.org's “Addressing Vaccination Anxiety” resources and additional VIS content. 

Pricing (includes all shipping and handling costs)

Laminated CDC VIS QR Code Table (English)
1 copy: $14.00
2 copies: $9.00 each
3–4 copies: $6.50 each
5–9 copies: $5.00 each
10–19 copies: $4.00 each
20–59 copies: $3.00 each
60+ copies: $2.50 each

Bundle: Laminated CDC (English) + Spanish Translation VIS QR Code Tables
(each bundle includes 1 CDC VIS table and 1 table of Spanish translations)
1 bundle: $20.00
2 bundles: $16.00 each
3–4 bundles: $12.00 each
5–9 bundles: $8.50 each
10–19 bundles: $7.00 each
20–59 bundles: $6.00 each
60+ bundles: $5.00 each



Visit the Shop Immunize.org: Laminated VIS QR Code Tables web page to view images and order today! For additional information, call 651-647-9009 or email admininfo@immunize.org. 

Confident healthcare provider recommendations for influenza vaccine are powerfully persuasive. As the nation faces a challenging influenza season, Immunize.org, in collaboration with CSL Seqirus, updated the 65+ Flu Defense website to help you maximize patient protection.



This helpful site includes information, tools, and tips for communicating with adults age 65 and older about the burden and severity of influenza. Resources include:

• Influenza in Adults 65+: The Facts
• Influenza Vaccination: Questions Patients Aged 65 and Older Frequently Ask Their HCP
• The Importance of Preventing Influenza and COVID-19

A clinician recommendation is the most important reason why a person will get vaccinated. Check out the updated 65+ Flu Defense website to assist your ongoing efforts in protecting this vulnerable population.

In its March 19 issue, PLOS Medicine published Association Between COVID-19 Vaccination and Sudden Death in Apparently Healthy Younger Individuals: A Population-Based Case-Control Study. No association was found. A portion of the author summary appears below.

• A case-control study was conducted involving Ontario residents aged 12–50 years without documented comorbidities predisposing to premature death between April 1, 2021 and June 30, 2023 to examine the association between COVID-19 vaccination and sudden death
• The primary outcome was sudden death; the exposure of interest was any COVID-19 vaccination
• Among 6,365,451 eligible individuals, 4,806 cases who experienced sudden death were matched to 24,030 controls who were alive on the date of sudden death for each corresponding case
• Receipt of COVID-19 vaccination was not associated with increased odds of sudden death . . .
• These findings do not support the hypothesis that COVID-19 vaccines increase the risk of sudden cardiac death in younger healthy adults

On February 25, Pediatrics published The Role and Safety of Aluminum Adjuvants in Childhood Vaccines. Studies show that aluminum released from intramuscular vaccines is slowly absorbed and efficiently cleared by the kidneys, contributing minimally to systemic levels. Large-scale studies consistently demonstrate no association between aluminum-adjuvanted vaccines and autism spectrum disorder, neurotoxicity, allergic disease, or autoimmune disease. A portion of the abstract appears below.

Aluminum salts have been used as adjuvants in vaccines for nearly a century, enhancing the immune response to purified antigens and ensuring durable protection against serious infectious diseases. Despite their longstanding record of safety and effectiveness, aluminum adjuvants have become a focus of public concern, with claims linking them to developmental, neurologic, allergic, and autoimmune diseases. This review summarizes the immunologic rationale for aluminum adjuvants and evaluates the evidence for proposed safety risks. . . . Collectively, the evidence strongly supports the safety of aluminum adjuvants and their necessity in certain vaccines. Clinicians can reassure caregivers that aluminum-containing vaccines provide clear benefits, with risks largely limited to transient local reactions and no systemic toxicity signal in large clinical and epidemiologic studies.

View the video.

 

Related Link

• Immunize.org: Adjuvants: Resources and Information main page

In its March 21 issue, NEJM published Communicating About Vaccines in a Politically Contentious Climate. A portion of the article appears below. 

Given the multitude of federal vaccine policy changes and the historical and anticipated struggles in communicating with parents about vaccines with an SDM [shared decision-making] recommendation, clinicians may find these conversations increasingly difficult. In this context, it may be helpful to remember what has remained constant: pediatric clinicians have been and continue to be parents’ most trusted source of reliable information about vaccines. It is important that clinicians both draw on this trust and nurture it.

To do so, pediatric clinicians should be careful about expressing a political stance or making overt political references in their vaccine discussions with parents. As decisions about whether to vaccinate become increasingly associated with political ideology, politics may more frequently enter these discussions. To avoid alienating parents and eroding trust, pediatric clinicians should engage about politics only when parents voice their own political views and should do so only to learn more about how those views are influencing their vaccine decision making.

An audio interview accompanies this article. 

In its March 20 issue, Pediatrics published COVID-19 mRNA Vaccination in Pregnancy and Risk of Infection in Early Childhood. COVID-19 vaccination during pregnancy protects the offspring against hospital contact for COVID-19 during the first 6 months of life. A portion of the video abstract appears below. 

Among 146,031 infants born in Norway in the study period, 37,013 (25%) were exposed to COVID-19 vaccination in pregnancy. There was no difference in the overall risk of any infection registered in specialist care among offspring exposed to maternal vaccination . . . The offspring’s protection against COVID-19 decreased over time . . . No notable difference in the risk of hospital contacts for infections other than COVID-19 was observed. 

A video abstract accompanies this article.

Health authorities are responding to a large outbreak of meningococcal B meningitis reported in Kent, England. The response includes targeted antibiotic treatment and MenB vaccination.

The UK Health Security Agency (UKHSA) is reminding teenagers and adults that two doses of MenB vaccine are needed for protection.

In the United States, CDC, the American Academy of Pediatrics, and the American Academy of Family Physicians recommend MenB for people age 10 and older who are at increased risk for meningococcal type B disease, including those with certain immune conditions (e.g., asplenia) and those at risk during outbreaks. For healthy people age 16 through 23 years who are not exposed to an outbreak, MenB vaccination is recommended based on shared clinical decision-making.

Because this is an active and evolving situation, UKHSA updates its Meningitis Outbreak: What You Need to Know blog page regularly.

Related Links

• UKHSA: Meningitis Outbreak: What You Need to Know blog
• WHO: Meningitis B Outbreak in the United Kingdom web page
• Immunize.org: Vaccines A–Z: Meningococcal B main page

To learn simple tips and tricks for using our websites efficiently, please register for our next set of Website Office Hours on Wednesday, April 8, at 4:00 p.m. (ET) or Thursday, April 9, at 12:00 p.m. (ET). The same content will be covered in both sessions.

We will open each 30-minute session with a short, live demonstration on navigating our About Us, Publication Archives, and Vaccine Timeline website sections. You can submit questions when you register or live on Zoom during the session.

Register today for Immunize.org Website Office Hours (content is the same for both):

• Wednesday, April 8, at 4:00 p.m. (ET)
• Thursday, April 9, at 12:00 p.m. (ET)

The archive of previous Website Office Hours content is posted at Immunize.org’s "Webinars & Videos" page.

Mark your calendar for future Immunize.org Website Office Hours.